Navigation Links
Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
Date:11/21/2007

e three weeks. Brostallicin was escalated from 5 to 7 to 9 mg/m2 with a fixed dose of cDDP of 75 mg/m2. To review the poster for more detailed information, please go to http://www.CTICSeattle.com.

About Brostallicin

Brostallicin, a novel synthetic second-generation DNA minor groove binder, has potent cancer killing activity and has demonstrated synergism in combination with standard cytotoxic agents as well as with newer targeted therapies in preclinical experimental tumors models. Brostallicin binds covalently to DNA within the DNA minor groove interfering with DNA division and leading to tumor cell death. More than 200 patients have been treated with brostallicin in single-agent and combination studies. Brostallicin had predictable and predominantly hematologic toxicities. Activity was demonstrated in a number of solid tumor types. A phase II study of brostallicin in relapsed/refractory soft tissue sarcoma met its pre-defined activity and safety hurdles and resulted in a first-line phase II study that

is currently being conducted by the European Organization for Research and Treatment of Cancer (EORTC).

About Systems Medicine (SM)

In July 2007, CTI acquired Systems Medicine (SM), a privately-held oncology company, in a stock-for-stock merger. SM applies a systems biology approach to drug development, combining pharmacogenomics and bioinformatics with experienced preclinical, clinical, and regulatory expertise to find and exploit a specific cancer's 'context of vulnerability.' Specifically, SM defines the molecular and genetic alterations (context) that cause cancer cells to be particularly sensitive (vulnerable) to a drug or combination of drugs -- the 'context of vulnerability'.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer mo
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Phase III Trial Finds Pharmaxis Bronchitol Effective
9. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
10. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... July 01, 2015 , ... It is now possible to separate ... single photon emission computed tomography (SPECT) according to researchers from Amen Clinics, UCLA, ... 20,000 brain scans and is believed to be the largest brain imaging study ever, ...
(Date:7/1/2015)... 1, 2015   Neuraltus Pharmaceuticals, Inc. , a ... groundbreaking drugs to treat neurodegenerative diseases such as ... Robert G. Miller , M.D., Director of the Forbes ... Pacific Medical Center in San Francisco, has been awarded ... million to help fund a Phase 2 clinical ...
(Date:7/1/2015)... ... 01, 2015 , ... Apex Therapeutics announced today that company CEO, David Broecker ... , The presentation took place on Tuesday, June 16 and provided an update ... APX3330 for the treatment of pancreatic cancer. A copy of the company overview ...
(Date:6/30/2015)... June 30, 2015 /PRNewswire/ - Resverlogix Corp. ("Resverlogix") ... shares of Resverlogix have approved the resolutions relating ... Limited of 5,600,000 units at a price of ... unit being comprised of one common share and ... of approximately CAD$15 million; and (ii) the amendment ...
Breaking Biology Technology:Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3
... new angel groups in Illinois as well as the emergence of ... funding. I have been struck by the continued increase in this ... the Midwests biotech companies are early stage in comparison to their ... of funding for this type of company in the Midwest. , ...
... a detailed look at how video games have affected the ... C. Beck and Mitchell Wade compiled personal ... how to handle the increasing number of professionals in the ... everything else are shaped by video games. , ,The ...
... Hospital and the Medical College of Wisconsin plan to ... their cancer center, to be completed in 2007. , ,The ... spring, that will give the center's clinical services room to ... hospital for cardiovascular and neuroscience outpatient services. , ,Froedtert President ...
Cached Biology Technology:Midwest angel investment in life sciences on the rise 2Midwest angel investment in life sciences on the rise 3Midwest angel investment in life sciences on the rise 4Midwest angel investment in life sciences on the rise 5Midwest angel investment in life sciences on the rise 6Got Game makes big claims; can 90 million people think the same? 2
(Date:6/16/2015)... -- With the increasing number and severity of data breaches ... recent compromise of Federal employee data from OPM,s ... government agencies. HYPR Corp. announced today that ... has been submitted for testing and approval of Federal ... tamper proofing. The proliferation of security ...
(Date:6/15/2015)... , June 16, 2015 According ... Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, ... to 2020" published by MarketsandMarkets, The Natural Language Processing ... a CAGR of 18.4% for the forecast period 2015-2020. ...   46 F igures spread   through 155 ...
(Date:6/12/2015)... 12, 2015  Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, announced the ... electronically capture, analyze and identify participants of a ... This system can: , ... and subsequent sign-on process is actually the person ...
Breaking Biology News(10 mins):Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2
... The University of Nottingham are to investigate the effect of ... ways of keeping up our strength as we get old. ... Medicine and Health in Derby, want to know what sort ... eat to slow down the natural loss of skeletal muscle ...
... 11, 2008 People who are asked whether they ... snack might not follow their intentions when the snacks ... of the Journal of Nutrition Education and Behavior ... inconsistency between healthful snack choice intentions and actual behavior. ...
... MENLO PARK, Calif., Sept. 10 Promptu, ... (Official Airline,Guide), a leading supplier of flight schedule ... they have signed an agreement to provide,mobile applications ... to the airline industry. Details of the agreement ...
Cached Biology News:A stronger future for the elderly 2Making snack food choices 2Promptu and OAG Team to Deliver Flight Schedule and Status Information on Mobile Devices 2Promptu and OAG Team to Deliver Flight Schedule and Status Information on Mobile Devices 3
The Programmable MP-5000P-F Power Supply can be applied for any Microfluidic application....
... Scientific has a long and outstanding ... apparatus. Several years ago we became ... microdispenser was being modified to inject ... by redesigning the microdispenser to eliminate ...
...
... designed for sequencing inserts cloned into M13/pUC-based ... T3 RNA polymerase promoters, or lambda gt10 ... a concentration of 0.1 µg/µl in water. ... sequencing reactions using SequiTherm™ EXCEL™ II DNA ...
Biology Products: